Overview

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill leukemia cells. PURPOSE: Phase III trial to study the effectiveness of high-dose combination chemotherapy, peripheral stem cell transplantation, and interleukin-2 in treating patients who have acute myeloid leukemia.

Phase:

Phase 3

Details

Lead Sponsor:

Roswell Park Cancer Institute

Treatments:

Aldesleukin
Cyclophosphamide
Cytarabine
Etoposide
Etoposide phosphate
Idarubicin
Interleukin-2
Melphalan